Spectrum Pharma begins patient enrollment in phase 1 trial evaluating safety ... - pharmabiz.com PDF Print
pharmabiz.com
Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperparathyroidism and cardiovascular disease, and is independently associated with

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.